Echo and The Vitamin Outlet Partner: Bringing Hydrogen Water Health to Australians
Echo has teamed up with The Vitamin Outlet to introduce the Echo Flask to Australia. This innovative, app-connected bottle infuses water with molecular hydrogen, offering a powerful antioxidant that supports energy, recovery, and overall cellular health.
The Echo Flask is an app-connected bottle that infuses water with molecular hydrogen — a powerful antioxidant that supports energy, recovery, and cellular health. Its advanced PEM technology delivers up to 8 ppm in 20 minutes.
'We're proud to offer the Echo Flask to our customers,' said Kwong Keet Chan, CEO of The Vitamin Outlet. 'It represents a new class of hydration — safe, convenient, and scientifically validated. It fits into our mission to provide premium wellness solutions that Australians can trust.'
Backed by peer-reviewed research, hydrogen water is gaining recognition for its potential to reduce oxidative stress and inflammation at the cellular level. The Echo Flask makes this wellness tool more accessible than ever.
'Australians are among the most engaged when it comes to preventative health,' said Josh Carr, CEO of Echo. 'Partnering with The Vitamin Outlet allows us to deliver an elite hydrogen wellness product to a market that values innovation and results.'
Available for AUD $470, the Echo Flask is now offered through The Vitamin Outlet's website and at their Bull Creek location in Perth.
Key Features of the Echo Flask
Generates 5 ppm in 10 minutes, 8 ppm in 20 minutes
Echo App for cycle control and hydration tracking
Lightweight 350 ml design
Smart touchscreen, USB-C charging
Chemical-free PEM tech — no byproducts or contaminants
A 5-year warranty
About Echo
Echo is a pioneer in hydrogen health, dedicated to helping people unlock and sustain peak performance by transforming water into a clean source of cellular support. From advanced home water systems to portable wellness solutions, Echo partners with the body to promote internal balance, resilience, and consistent energy. Backed by peer-reviewed science, trusted by health experts, and engineered for everyday living, Echo makes hydrogen health accessible, effective, and transformative. For more information, visit www.echowater.com.
About The Vitamin Outlet
With both an online platform and physical presence in Perth, The Vitamin Outlet is a go-to destination for trusted wellness products in Australia. It curates scientifically backed tools that help Australians live better, naturally — combining integrity, education, and service to meet the needs of today's informed consumer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
26 minutes ago
- Business Wire
Bardavon Launches Online Physical Medicine Portal Benefiting Claims Adjusters and Nurse Case Managers
OVERLAND PARK, Kan.--(BUSINESS WIRE)--Bardavon is proud to announce the launch of Link, a new digital portal designed specifically for Adjusters and Nurse Case Managers (NCMs). This platform brings clarity, efficiency, and actionable insight to the forefront of injury case management and physical rehabilitation. Link is a one-stop online destination that gives Adjusters and NCMs 24/7 access to the information they need, when they need it. Key features of Link include: At-a-glance case summaries including actual visit counts, estimated case duration, and authorized visits remaining Snapshot views of patient case status such as current risk level, no-shows, care gaps, and reauthorization needs Easy access to view and download all case notes, updated nightly and viewable in-line with the patient record Comprehensive case details including appointments, attendance, predictive analytics, and open items requiring action Quality oversight includes clinical team case interventions for treating therapist and alerts to stakeholders regarding case progression All information is refreshed nightly to ensure timely and accurate updates. With Link, Bardavon takes information that was previously provided to Adjusters and NCMs incrementally via e-mail or fax and now presents it in an easily digestible and meaningful manner to generate actionable insights. Link is built on the same platform that Bardavon's clinical oversight team uses every day, effectively providing Adjusters and NCMs the same 360 degree case management view as Bardavon's clinical oversight staff. 'We're excited to roll out the Link online portal as part of our commitment to building tools and workflow guides focused on supporting Adjusters and Nurse Case Managers, with the hope of supercharging their workflow,' said Jen Henry, VP of Clinical Operations and Services at Bardavon. 'Link empowers our partners to proactively manage cases, access critical insights, and take timely action to keep care on track. Most importantly, it allows them to manage cases on their time, with the certainty of complete and consolidated case information.' Why Link? The name reflects the portal's core purpose: linking stakeholders to timely, relevant information, in turn fostering stronger collaboration, better communication, and accelerated case progression. Over time, Link will evolve to include additional features such as one-click access to submit new referrals and re-authorizations, visibility to the status of new referrals, and more. Built on the same platform as Bardavon's clinical coaching portal, Link pulls from the same prioritized clinical and administrative data set, providing Adjusters and NCMs the information they need, accessible when they want it. Bardavon recognizes that every adjuster and case manager works differently—which is why Link will never be mandatory. We pride ourselves on listening to our clients and making sure communication and reporting preferences can be tailored at the individual user level, whether that means using Link or continuing to receive notes and case-level details via email or fax. And just like other Bardavon program enhancements, such as Recovery+, there is no charge or fee associated with Link. "Ultimately, we see the release of Link as a natural extension of our commitment to developing tools that make the jobs of Nurse Case Managers and Adjusters easier, better, and more straight-forward,' said Sarah Meyer, Chief Operating Officer at Bardavon. 'Our focus is on meeting each end user where they are—adapting to their preferred workflow and timing, so they can work in the way that suits them best." To learn more about the Link portal, visit Bardavon is a nationwide network of PT/OT providers treating workplace injuries while focusing on the unique needs of each injured worker and their return-to-work goals. Our high-touch, tech-enabled service enhances and simplifies the patient management experience for each stakeholder, including payers, adjusters, case managers, and injured workers. This optimizes claims outcomes and reduces costs. To learn more, visit
Business Wire
an hour ago
- Business Wire
Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced that its candidate VE202 did not meet the primary endpoint of endoscopic response in the Phase 2 COLLECTiVE202 study for the treatment of patients with mild-to-moderate ulcerative colitis (UC). 'We are very disappointed that our study did not meet its efficacy endpoints, and our greatest regret is that people living with inflammatory bowel disease will not, for now, have the opportunity to benefit from a new treatment option,' said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences. 'The gut microbiome is a well-recognized driver of IBD, yet remains a facet of the disease untouched by current treatments. As a field, we have not yet succeeded in making a meaningful impact for people with IBD through microbiome-based approaches, but every study moves us closer to that goal. We are committed to sharing further analyses of this study at upcoming scientific meetings to help chart new paths forward.' 'Our priority at Vedanta remains the successful execution of our ongoing global pivotal study of VE303 for the prevention of recurrent C. difficile infection, with the goal of potentially delivering the first approved Live Biotherapeutic Product in any indication — and, in doing so, addressing a serious health condition with a significant unmet medical need,' concluded Dr. Olle. In the randomized, placebo-controlled COLLECTiVE202 study, endoscopic and clinical responses were assessed using standardized criteria, and the observed response rates in the VE202 group were not statistically different from those in the placebo group. VE202 was generally safe and well tolerated — most adverse events were mild or moderate in intensity, with no reports of treatment-related serious adverse events. Analyses of bacterial colonization, histological findings, and immune responses are ongoing and will be shared in future scientific forums. Vedanta remains focused on advancing its other pipeline programs: VE303: Vedanta is currently enrolling patients into RESTORATiVE303, a registrational Phase 3 study of VE303 for the prevention of recurrent C. difficile infection (rCDI) at over 200 sites in 24 countries. The Phase 3 program is supported by results from a positive Phase 2 study, in which VE303 demonstrated potentially best-in-disease efficacy with a 30.5% absolute risk reduction compared with placebo and greater than 80% reduction in the odds of a CDI recurrence. VE707: Vedanta is also advancing VE707 to prevent infections by multidrug-resistant organisms that affect a wide range of vulnerable populations in areas such as oncology, urology, transplantation, and critical care, with IND submission planned for 1H 2026. About the COLLECTiVE202 Study COLLECTiVE202 is a double-blind, placebo-controlled, randomized clinical trial conducted at sites in the United States, Europe, and Australia. The study enrolled 114 patients, between the ages of 18 and 75 years, with mild-to-moderate ulcerative colitis who had not been exposed to any biologic or advanced oral therapies. Either VE202 (N=57) or placebo (N=57) was added to a patient's stable background ulcerative colitis therapy. The primary endpoints were safety and Week 8 endoscopic response (defined as a reduction of at least 1 point on the Mayo endoscopic subscore). Secondary endpoints included clinical response and remission, endoscopic improvement and remission, as well as histological assessments and measures of colonization, quality-of-life and inflammatory biomarkers. For more information on COLLECTiVE202 (NCT05370885), visit About Vedanta Biosciences Vedanta Biosciences is a clinical-stage biopharmaceutical company developing microbiome-based oral medicines for the treatment of gastrointestinal diseases. The company's lead asset is a potential first-in-class therapy, VE303, currently in a global Phase 3 registrational trial for prevention of recurrent C. difficile infection. Vedanta leverages its proprietary industry-leading product engine to develop therapeutic drug candidates based on defined bacterial consortia. The product engine is supported by broad foundational intellectual property and spans the development lifecycle from discovery to commercialization. It includes one of the largest libraries of bacteria isolated from the human microbiome, vast clinical datasets, proprietary capabilities in consortium design, and end-to-end CGMP manufacturing capabilities at commercial launch scale.
Business Wire
2 hours ago
- Business Wire
Zai Lab Establishes Oncology Scientific Advisory Board
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the creation of its Oncology Scientific Advisory Board (SAB). The newly formed Oncology SAB is comprised of distinguished oncology leaders and will support the advancement of the Company's robust oncology products and pipeline, including multiple internally developed investigational therapies. 'We are honored to bring together this esteemed group of oncology leaders who will support our continued development and advancement of innovative treatment options for patients globally,' said Rafael G. Amado, M.D., President, Head of Global Research and Development, Zai Lab. 'The formation of this Board is an important step for Zai; we know our clinical programs will benefit tremendously from the guidance and perspective of this highly regarded and experienced group of individuals.' Zai Lab's Oncology SAB comprises the following: Lieping Chen, M.D., Ph.D., is a United Technologies Corporation chair in cancer research, professor of immunobiology, dermatology and medicine at the Yale University School of Medicine. Richard S. Finn, M.D., is director of the Signal Transduction Program in the Jonsson Comprehensive Cancer Center at University of California, Los Angeles (UCLA). Thomas F. Gajewski, M.D., Ph.D., directs the Melanoma Oncology Clinic and leads the Immunology and Cancer Program at the University of Chicago Comprehensive Cancer Center. Melissa L. Johnson, M.D., directs lung cancer research at the Sarah Cannon Research Institute. Matthew Krebs, M.D., Ph.D., is a clinical senior lecturer in experimental cancer medicine at the University of Manchester and leads early phase clinical trials at The Christie NHS Foundation Trust, Manchester, U.K. Patricia LoRusso, M.D., D.O., is director of the Early Phase Clinical Trials Program and Associate Center Director of Experimental Therapeutics at Yale Cancer Center. Michael T. Lotze, M.D., FACS, is professor of surgery, immunology and bioengineering, and director of the DAMP Laboratories at the University of Pittsburgh Medical Center Hillman Cancer Center. Timothy Yap, M.B.B.S., Ph.D., FRCP, is a medical oncologist, physician-scientist and professor at the University of Texas MD Anderson Cancer Center. About Zai Lab Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health worldwide. For additional information about Zai Lab, please visit or follow us at Zai Lab Forward-Looking Statements This press release contains forward-looking statements relating to our future expectations, plans, and prospects for Zai Lab, including, without limitation, statements relating to our prospects and plans for developing and commercializing our oncology products and pipeline. These forward-looking statements may contain words such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'plan,' 'possible,' 'potential,' 'will,' 'would,' and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at and on the SEC's website at
